Terns Pharmaceuticals (TERN) Amortization of Deferred Charges (2020 - 2023)
Historic Amortization of Deferred Charges for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$1.7 million.
- Terns Pharmaceuticals' Amortization of Deferred Charges fell 19734.98% to -$1.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$5.2 million, marking a year-over-year decrease of 653580.25%. This contributed to the annual value of -$2.1 million for FY2024, which is 5990.79% up from last year.
- According to the latest figures from Q4 2023, Terns Pharmaceuticals' Amortization of Deferred Charges is -$1.7 million, which was down 19734.98% from -$1.7 million recorded in Q3 2023.
- In the past 5 years, Terns Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $613000.0 in Q1 2022 and a low of -$1.7 million during Q3 2023
- Its 4-year average for Amortization of Deferred Charges is -$324307.7, with a median of -$3000.0 in 2021.
- In the last 5 years, Terns Pharmaceuticals' Amortization of Deferred Charges surged by 2053333.33% in 2022 and then plummeted by 662692.31% in 2023.
- Terns Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $37000.0 in 2020, then soared by 424.32% to $194000.0 in 2021, then tumbled by 391.75% to -$566000.0 in 2022, then crashed by 197.35% to -$1.7 million in 2023.
- Its last three reported values are -$1.7 million in Q4 2023, -$1.7 million for Q3 2023, and -$975000.0 during Q2 2023.